VEGFA and hepatocellular carcinoma: The first approved drug for advanced HCC, which was the tyrosine kinase inhibitor (TKI) sorafenib, provided only a modest survival benefit of 2 to 3 months with low response rates, high toxicity often requiring dose reduction or treatment interruption, and frequent development of resistance, and was followed by several other TKIs (lenvatinib, regorafenib, cabozantinib) and ramucirumab, an antibody against vascular endothelial growth factor A (VEGFA) receptor 2 (4–6).